Crushbiotech.comhttp://www.crushbiotech.com/Most recent articles from CrushBiotechen-usSangamo releasing results of p2b in diabetic neuropathy on Monday morninghttp://www.crushbiotech.com/articles/view/sangamo_releasing_results_of_p2b_in_diabetic_neuropathy_on_monday_morninghttp://www.crushbiotech.com/articles/view/sangamo_releasing_results_of_p2b_in_diabetic_neuropathy_on_monday_morningPress Release Source: Sangamo BioSciences, Inc. On Friday September 30, 2011, 5:40 pm EDTRICHMOND, Calif., Sept. 30, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. ...DavidTannenbaumFri, 30 Sep 2011 19:16:01 -04002Q Sangamo Earnings and CC Reviewhttp://www.crushbiotech.com/articles/view/2q_sangamo_earnings_and_cc_reviewhttp://www.crushbiotech.com/articles/view/2q_sangamo_earnings_and_cc_reviewSangamo today announced results for its 2Q of 2011.  The low revenue indicates that royalties from the 2 ZFP partner programs has still not accelerated.  However, the most important...DavidTannenbaumWed, 27 Jul 2011 16:18:26 -0400Sangamo going to be data rich in the second half of 2011http://www.crushbiotech.com/articles/view/sangamo_going_to_be_data_rich_in_the_second_half_of_2011http://www.crushbiotech.com/articles/view/sangamo_going_to_be_data_rich_in_the_second_half_of_2011There are two major catalysts upcoming for Sangamo Biosciences in the second half of 2011: Top-line results from their Phase IIb study in diabetic neuropathy for SB-509 and preliminary results...DavidTannenbaumMon, 25 Jul 2011 15:09:06 -0400